# A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

> **NCT03246529** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **BioLineRx, Ltd.** · enrollment: 180 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** BL-8040 1.25 mg/kg + G-CSF
- **DRUG:** Placebo +G-CSF

## Key facts

- **NCT ID:** NCT03246529
- **Lead sponsor:** BioLineRx, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-03-23
- **Primary completion:** 2020-12-22
- **Final completion:** 2029-09-30
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03246529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03246529, "A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03246529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*